FDA.gov (2026) 10
There may also be minor irritation at the injection site, for example, redness, tenderness, or a brief burning sensation where the NAD+ solution is injected subcutaneously
FDA Advisory Committee Votes to Ease Peptide Restrictions: What the July 2026 Vote on BPC-157, KPV, TB-500, and MOTS-c Actually Means An FDA advisory committee voted on July 23, 2026 to recommend easing restrictions on four peptides BPC-157, KPV, TB-500, and MOTS-c
Schedule a visit, ask a question, or start a plan now
However, during an initial loading phase, a more frequent schedule may be necessary